Andrew Merseth, analyst at Decision Resources is available to comment on the impact to the pharmaceutical industry of the U.S. Senate committee's approval of biogenerics legislation. A U.S. Senate committee voted on Wednesday in favor of legislation that would allow the FDA to approve biogeneric drugs, and the bill, "The Biologics Price Competition and Innovation Act of 2007," will now head for the Senate floor. Biotechnology firms who oppose the bill have suggested that their products are too difficult to copy without risking dangerous side effects.

Decision Resources recently conducted a survey at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this month. The analyst firm found that oncologists are extremely willing to begin prescribing biogeneric forms of oncology products. Sixty percent of respondents said they would be willing to prescribe biogeneric Epogen/Procrit, biogeneric Neupogen, and biogeneric Herceptin within six months of its release. For possible biogeneric forms of Rituxan and Campath, the majority of oncologists said they would prescribe biogeneric versions within one year. While Sandoz was able to get a version of Omnitrope approved last year, there is no existing pathway for biogeneric versions of the vast majority of biologics in the United States. This pending new legislation would for the first time allow FDA to approve these "follow-on biologics"-including these five key oncology products.

  Mr. Merseth can answer the following questions:    -- What is the impact of this legislation on the biotech and generic      industries?   -- How soon do we expect biogenerics to arrive?   -- How quickly will U.S. physicians adopt biogenerics?   -- How much will these biogenerics cost and how much can we expect to      save?   -- What will branded companies do in the face of biogeneric competition?  

To speak with Mr. Merseth, please contact Liz Marshall at 781-296-2563 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Anti-Competitive Concerns Linger Over Pennsylvania Blues Merger

View Now